The aim is to reduce the biopharma’s R&D workforce by more than 35% compared with 2025 levels, with the associated cost ...

Evommune has agreed to pay $30 million to China’s Hinova Pharmaceuticals to get stuck into a niche of preclinical molecular ...

MetaVia has linked its GLP-1/glucagon receptor agonist to reductions in liver fat and body weight in a phase 1 trial.

Vivoryon Therapeutics has regained the China rights to its kidney disease prospect as the German biotech’s cash reserves ...